PharmiWeb Recruiter Blog

Initial grants of approximately $5 million awarded to local and global nonprofits that support groups and causes disproportionately affected by COVID-19

Paris, April 4, 2022. Sanofi launches today its Diversity, Equity & Inclusion (DE&I) Board, the first-of-its-kind in the pharmaceutical industry to feature outside advisors. Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand.

- Abbott and LISC invest more than $37 million to empower and grow diverse small businesses that provide manufacturing and essential products for healthcare companies

Scenic Biotech and the Barth Syndrome Foundation Announce Partnership to Explore Genetic Modifiers to a Find Tailored Treatment for the Complex Rare Disease

• Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
• Collaboration to create, develop, manufacture and commercialize new class of potential therapeutics combining the superior features of multi-valent IgM antibodies over conventional IgG antibodies for stimulating cell surface receptors
• IGM to receive $150 million upfront payments, potentially over $6 billion in aggregate development, regulatory and commercial milestones

Paris, March 29, 2022 – Sanofi (NASDAQ: SNY) and IGM Biosciences, Inc. (Nasdaq: IGMS) today announced the signing of an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets. Engineered IgM antibodies represent a new class of potential therapeutics that combine the multi-valency of IgM antibodies possessing 10 binding sites compared to conventional IgG antibodies having only 2 target binding sites.

Establishment of the first end-to-end Australian capability for product development and commercial scale production of mRNA, DNA and recombinant vaccines 

• Construction begins on a new state-of-the-art manufacturing facility at Kent Science Park designed to support the manufacture of regulatory approved cannabis-based medicines
• This represents a significant commitment to the UK by GW Pharmaceuticals, now part of Jazz Pharmaceuticals, investing $100 million (£75m) and creating more than 100 highly skilled jobs

LONDON, March 25, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and its subsidiary, GW Pharmaceuticals ("GW") – a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines – today announced the official initiation of construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne.

On-shore manufacturing facility based in Melbourne, Australia, expected to produce up to 100 million mRNA respiratory vaccine doses annually

• Collaboration will utilize Avatar-Rx, LifeMine’s proprietary genomically-enabled drug discovery platform to access evolutionarily derived lead small molecules
• Potential to identify novel product candidates to modulate difficult-to-drug targets across multiple disease areas

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced a strategic R&D collaboration with GlaxoSmithKline (GSK). The collaboration will provide GSK with access to LifeMine’s genomically enabled drug discovery platform to identify novel small molecule leads directed to up to three human targets provided by GSK addressing multiple disease areas.

SUZHOU, China, March 22, 2022, Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has established a global clinical collaboration with Bristol Myers Squibb to evaluate the combination of TST001, an investigational humanized monoclonal antibody targeting Claudin18.2 developed by Transcenta, with Opdivo® (nivolumab), Bristol Myers Squibb's anti-PD-1 therapy, for the treatment of patients with unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction cancer (GC/GEJ).